Sandbox: malabsorption: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 132: Line 132:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* [[Iron deficiency]]
* [[Iron deficiency]]
* [[Vitamin B12]] deficiency
* [[Vitamin B12]] deficiency
* Elevated [[erythrocyte sedimentation rate]]  
* Elevated [[erythrocyte sedimentation rate|ESR]]  
* Elevated [[C-reactive protein|CRP]]
* Elevated [[C-reactive protein|CRP]]
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
Line 148: Line 148:
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |30-50
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |30-50
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |+/-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |±
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |  
Line 178: Line 178:
* [[Abdominal distention]]
* [[Abdominal distention]]
* Abdominal RUQ tenderness
* Abdominal RUQ tenderness
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |-
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
| style="padding: 5px 5px; background: #F5F5F5;" align="left" |
*Elevated [[VIP]] level
*[[Hypokalemia]]
*[[Hypokalemia]]
*[[Hypochlorhydria]] or [[achlorhydria]]
*[[Hypochlorhydria]] or [[achlorhydria]]
Line 197: Line 198:
* Followed by imaging
* Followed by imaging
|-
|-
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]])
! align="center" style="background:#DCDCDC;" |[[Zollinger-Ellison syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | 20-50
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |20-50
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |

Revision as of 22:18, 9 November 2017

Abbreviations: WBC: White blood cells; Plt: Platelets, Hgb: Hemoglobin, IgE: Immunoglobulin E, IgA: Immunoglobulin A

Cause Peak age of onset History Physical exam Lab findings Additional findings Cause/Pathogenesis Gold standard diagnosis
Fever Abdominal pain Diarrhea Weight loss
Watery Fatty WBC Hgb Plt Other lab findings
Whipple's disease 40-60 ± + + + + ↓/↑
Celiac disease Childhood

Adult

- + +/- +/- + - -
  • IgA endomysial antibody
  • Anti-tissue transglutaminase antibody
  • Anti-gliadin antibody
  • IgA endomysial antibody
  • IgA tissue transglutaminase antibody
Cystic fibrosis Childhood

Adult

± + - + + - -
  • Positive DNA analysis for CFTR
  • Evaluated nasal transepithelial potential difference (NPD)
Crohns disease Young adults

(20th)

+ + + + +
  • Abnormal immune response to self antigens
Irritable bowel syndrome 30-50 - ± ± ± - - - -
  • Diagnosis of exclusion
VIPoma 30-50 - + + + + - - -
  • Primary secretory tumor
  • Elevated VIP levels
  • Followed by imaging
Zollinger-Ellison syndrome 20-50
  • Elevated basal or stimulated serum gastrin> 1000 pg/mL
Lactose intolerance Any age +
Eosinophilic gastroenteritis  30th - + + + + - -
Primary bile acid malabsorption Childhood Adult
  • Total and specific bile acids from stool
  • Gamma emitter selenium-75-homocholic acid taurine (SeHCAT)
Abetalipoproteinemia Infancy

Adult

- - -
Microscopic colitis 50-70 - + + - + - -
Hyperthyroidism Any age ± + + - + - - -
  • Elevated T4
  • Elevated T3
  • Decreased TSH
Grain allergy Childhood - + + - +